Open AccessEvaluation of Metformin Hydrochloride Tailoring Bilosomes as an Effective Transdermal Nanocarrier
Author(s) -
Heba F. Salem,
Mohammed M. Nafady,
Adel A. Ali,
Nermeen M Khalil,
Amani A Elsisi
Publication year - 2022
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s345505
Subject(s) - transdermal , nanocarriers , zeta potential , fourier transform infrared spectroscopy , chemistry , drug delivery , materials science , dispersity , pulmonary surfactant , vesicle , factorial experiment , chromatography , nuclear chemistry , pharmacology , nanoparticle , nanotechnology , chemical engineering , polymer chemistry , medicine , membrane , biochemistry , statistics , mathematics , engineering
Metformin hydrochloride (metformin HCL), a first-line drug treating diabetes type II, was known to cause severe gastritis, so seeking a non-oral dosage form was the new trend. Bilosomes are bilayer nano-vesicles of non-ionic surfactants embodying bile salts. In our study, bilosomes were investigated as an acceptable novel carrier for active targeting transdermal delivery of metformin HCL, circumventing its side effects.